✦ LIBER ✦

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

✍ Scribed by Masayuki Takeda, Isamu Okamoto, Takeharu Yamanaka, Kazuhiko Nakagawa, Yoichi Nakanishi

Book ID: 119897381
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 149 KB
Volume: 12
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-12-327

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase IIIb Trial Evaluating t

Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial

✍ Cesare Gridelli; Jaafar Bennouna; Javier de Castro; Anne-Marie C. Dingemans; Fra 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 268 KB

A phase II study of erlotinib in combina

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer

✍ Ciuleanu, T.; Tsai, C.-M.; Tsao, C.-J.; Milanowski, J.; Amoroso, D.; Heo, D.S.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 718 KB

Randomized Phase III Trial of Maintenanc

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)

✍ Barlesi, F.; Scherpereel, A.; Rittmeyer, A.; Pazzola, A.; Ferrer Tur, N.; Kim, J 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 188 KB

PointBreak: A Randomized Phase III Study

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer

✍ Patel, J. D.; Socinski, M. A.; Garon, E. B.; Reynolds, C. H.; Spigel, D. R.; Ols 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 243 KB

Randomized phase II study of first-line

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer

✍ Niho, Seiji; Kunitoh, Hideo; Nokihara, Hiroshi; Horai, Takeshi; Ichinose, Yukito 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 408 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB